Aclaris Therapeutics (ACRS) Long-Term Debt Repayments (2018)
Aclaris Therapeutics (ACRS) recorded quarterly Long-Term Debt Repayments of $149000.0 in Q4 2018, down 9.15% quarter-over-quarter from $164000.0 in Q3 2018.
Aclaris Therapeutics (ACRS) Long-Term Debt Repayments (2018) Analysis & Trends
Aclaris Therapeutics' Long-Term Debt Repayments history runs 1 years deep, the most recent figure standing at $149000.0 for Q4 2018.
- In Q4 2018, Long-Term Debt Repayments changed N/A year-over-year to $149000.0; the TTM figure through Dec 2021 stood at $612000.0 (changed N/A YoY), while the FY2021 annual figure was -$11.5 million, changed N/A from the prior year.
- Long-Term Debt Repayments was $149000.0 for Q4 2018 at Aclaris Therapeutics, down from $164000.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $299000.0 in Q2 2018 to a low of $36000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -21,671.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Aclaris Therapeutics | 580.93 Mn | 580.93 Mn | 1.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 149,000.00 |
| Dec 31, 2018 | 149,000.00 |
| Sep 30, 2018 | 164,000.00 |
| Sep 30, 2018 | 164,000.00 |
| Jun 30, 2018 | 299,000.00 |
| Jun 30, 2018 | 299,000.00 |
| Mar 31, 2018 | 36,000.00 |
| Mar 31, 2018 | 36,000.00 |